Screening for hepatocellular carcinoma: Good enough but best yet to come

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 845-846

  Amarapurkar, Deepak ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AFP PROTEIN, HUMAN; VIRUS DNA;

ADULT; ALCOHOL LIVER CIRRHOSIS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EARLY CANCER; EDITORIAL; FEMALE; HEALTH SURVEY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ULTRASOUND; AMBULATORY CARE; CARCINOMA, HEPATOCELLULAR; COMPLICATION; COST BENEFIT ANALYSIS; ECHOGRAPHY; ECONOMICS; HOSPITAL COST; INCIDENCE; LIVER; LIVER NEOPLASMS; MASS SCREENING; MORTALITY; PATIENT CARE; PREDICTIVE VALUE; PROCEDURES; TEACHING HOSPITAL; TIME; VIROLOGY; ALCOHOLISM; CANCER PROGNOSIS; DIABETES MELLITUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALPHA-FETOPROTEINS; AMBULATORY CARE; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; HEPATITIS B, CHRONIC; HOSPITAL COSTS; HOSPITALS, TEACHING; HUMANS; INCIDENCE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; PATIENT CARE TEAM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TIME FACTORS;

EID: 77951763434     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06276.x     Document Type: Editorial

References (14)

1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 2008 48 (Suppl. 1 S20 37.
2. Yuen MF, Hou JL, Chutapurri A. Asia Pacific Working Party Prevention of Hepatacocellular Carcinoma. Hepatocellular carcinoma in the Asia Pacific Region. J. Gastroenterol. Hepatol. 2009 24 : 346 353.
3. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res. 2007 37 (Suppl. 2 S88 94.
4. Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vega O et al. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis and long term follow up study. Clin. Oncol. R. Coll. Radio. 2007 19 : 97 103.
5. Toyoda H, Kumada T, Kiriyama S et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin. Gastroenterol. Hepatol. 2006 4 : 1170 1176. Epub 2006 Aug 2.
6. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J. Hepatol. 2003 39 : 1076 1084.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
8. Amarapurkar DN, Han KH, Chan HLY, Ueno Y. Application of Surveillance Programs For Hepatocellular Carcinoma in the Asia Pacific Region. J. Gastroenterol. Hepatol. 2009 24 : 955 961.
9. Davila JA, Weston A, Smalley W, El-Serag HB. Utilization of screening for hepatocellular carcinoma in the United States. J. Clin. Gastroenterol. 2007 41 : 777 782.
10. Poustchi H, George J, Labio E et al. Screening for liver cancer: feasibility of randomized control trial. Hepatology 2005 42 (Suppl. 1 376A.
11. Stravitz RT, Heuman DM, Chand N et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am. J. Med. 2008 121 : 119 126.
12. Singhal A, Volk ML, Waljee A et al. Meta analysis: surveillance with ultrasound for early stage hepatocellular carcinoma in patients with cirrhosis. Aliment. Pharmacol. Ther. 2009 30 : 37 47.
13. Thomsan CJ, Rogers G, Hewson P et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol. Assess. 2007 11 : 1 206.
14. Qian MYY, Rong YJ, Angus P, Schelleman T, Johnson L, Gow P. Efficacy and cost of hepatocellular carcinoma screening program at an Australian teaching hospital. J. Gastroenterol. Hepatol. 2010 25 : 951 956.